Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5999540

CCC(c1ccccc1)c1cccc(F)c1.N

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.47
TDO2 P48775 1/20 0.47
SLC6A4 P31645 3/20 0.43
SLC6A2 P23975 2/20 0.43
CNR2 P34972 1/20 0.43
CYP19A1 P11511 1/20 0.42
AOC3 Q16853 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
LMNA P02545 1/20 0.41
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23126406 0.98 IDO1 (0.49) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL6001307 0.96 IDO1 (0.46) IDO1TDO2SLC6A4SLC6A2CNR2
Methylamine SCHEMBL6900406 0.94 IDO1 (0.50) IDO1TDO2SLC6A4SLC6A2CNR2
SCHEMBL22048343 0.94 IDO1 (0.47) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL6001477 0.91 IDO1 (0.42) IDO1TDO2SLC6A4SLC6A2CNR2
SCHEMBL21910600 0.91 IDO1 (0.42) IDO1TDO2SLC6A4SLC6A2CNR2
Methylamine SCHEMBL6000383 0.90 IDO1 (0.49) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL5999523 0.90 ACHE (0.42) IDO1TDO2SLC6A4SLC6A2CYP19A1
Dimethylamine SCHEMBL6001286 0.89 SLC6A4 (0.44) IDO1TDO2SLC6A4SLC6A2CNR2
Ethylamine SCHEMBL6001271 0.89 IDO1 (0.47) IDO1TDO2SLC6A4SLC6A2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases MUELLER ALAN L 2006-06-29 US disclosed
US-6750244-B2 NERVOUS SYSTEM DISORDERS NPS PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-6211245-B1 DRUGS FOR CONTROLLING CALCIUM MODULATORS NPS PHARMACEUTICALS, INC. 2001-04-03 US disclosed
US-6017965-A TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA NPS PHARMACEUTICALS, INC. (US) 2000-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NCS1, ATP2A1, CACNA1D IDO1 3661/4885TDO2 3085/4885SLC6A4 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.